As we have previously reported in this blog, innovation is not a major focus for many of the largest diagnostics companies. With but a few exceptions, the focus for the largest companies tends to be on selling instrumentation and on developing “me-too” tests, which...
Having recently conducted an analysis of biomarker panels in FDA-approved tests, we are now beginning to analyze biomarker panels in laboratory-developed tests (LDTs). To my knowledge this is the first publicly available analysis of LDTs. Utilizing a proprietary data...
